

SpringerBriefs in Immunology

More information about this series at <http://www.springer.com/series/10916>

Marek Jankowski · Tomasz Wandtke

Interleukin-27: Biological Properties and Clinical Application

 Springer

Marek Jankowski
Chair of Dermatology, Sexually Transmitted
Diseases and Immunodermatology,
Faculty of Medicine
Nicolaus Copernicus University in Toruń
Bydgoszcz
Poland

Tomasz Wandtke
Department of Gene Therapy, Faculty of
Medicine
Nicolaus Copernicus University in Toruń
Bydgoszcz
Poland

ISSN 2194-2773

SpringerBriefs in Immunology

ISBN 978-3-319-39662-0

DOI 10.1007/978-3-319-39664-4

ISSN 2194-2781 (electronic)

ISBN 978-3-319-39664-4 (eBook)

Library of Congress Control Number: 2016940341

© The Author(s) 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Illustrations by Marta Jakubowska

Printed on acid-free paper

This Springer imprint is published by Springer Nature

The registered company is Springer International Publishing AG Switzerland

Contents

1 IL-27: Structure, Regulation, and Variability	1
1.1 IL-27 and Its Receptors	1
1.1.1 The IL-27 Protein	1
1.1.2 Cell Membrane IL-27 Receptor	3
1.1.3 Soluble IL-27 Receptor	3
1.2 The Landscape of IL-27-Related Proteins	4
1.2.1 IL-30	4
1.2.2 IL-27p28/CLF	6
1.2.3 IL-35	7
1.2.4 Monomeric EB13	8
1.2.5 Intracellular EB13	8
1.3 Regulation of IL-27 Expression	8
1.3.1 Regulation of EB13 Expression	10
1.3.2 Regulation of IL-27p28 Expression	11
1.4 IL-27 Gene Variability	15
References	18
2 IL-27: A Key Player in Immune Regulation	27
2.1 IL-27 Receptor Downstream Signaling	27
2.2 Proinflammatory Effects of IL-27	29
2.2.1 IL-27 Promotes Th1 Cell Differentiation	29
2.2.2 IL-27 Augments CD8+ T Cell-Mediated Cytotoxicity	30
2.2.3 IL-27 Augments NK Cell-Mediated Cytotoxicity	31
2.2.4 IL-27 Positively Regulates T Follicular Helper (Tfh) Cells	32
2.2.5 IL-27 Is a Positive Regulator of B Cells	32
2.3 Anti-inflammatory Effects of IL-27	33
2.3.1 IL-27 Inhibits Th2 Response	33
2.3.2 IL-27 Has Dual Effects of FOXP3+ T Regulatory Cells	34

2.3.3	IL-27 Is a Positive Regulator of IL-10+ Regulatory T Cells (Tr1)	35
2.3.4	IL-27 Suppresses Th17 Helper Lymphocytes	36
2.3.5	IL-27 Limits Activity of Dendritic Cells and Macrophages	37
2.4	Effects of IL-27 in Epithelial Cells.	38
	References	39
3	IL-27 in Health and Disease	47
3.1	IL-27 in Infectious Diseases	47
3.1.1	Antiviral Properties of IL-27.	47
3.1.2	IL-27 Limits Antibacterial Defense Mechanisms	49
3.1.3	IL-27 Compromises Control of Mycobacterium.	50
3.1.4	The Role of IL-27 in Parasitic Infections	52
3.2	IL-27 in Inflammatory Diseases.	53
3.2.1	Protective Role of IL-27 in Atherosclerosis	53
3.2.2	IL-27 in Psoriasis	53
3.2.3	IL-27 in Inflammatory Bowel Disease	55
3.2.4	IL-27 in Pulmonary Inflammation	57
3.3	IL 27 in Autoimmunity	59
3.3.1	Role of IL-27 in Autoimmune Connective Tissue Diseases.	59
3.3.2	Role of IL-27 in Bone Remodeling and Rheumatoid Arthritis	60
3.3.3	IL-27 in Autoimmune Uveitis.	62
3.3.4	Protective Role of IL-27 in Autoimmune Encephalitis	63
3.3.5	IL-27 as a Pathogenic Factor in Immune Thrombocytopenia.	65
3.4	IL-27 in Fetomaternal Tolerance	66
3.5	IL-27 in Cancer.	67
3.5.1	IL-27 Stimulates Tumor-Directed Cytotoxicity	67
3.5.2	IL-27 Stimulates Macrophage-Dependent Tumor Immunity	68
3.5.3	IL-27 Impairs Tumor Vascularization.	69
3.5.4	IL-27 Has Direct Cytostatic and Proapoptotic Activity.	69
3.5.5	Potential Protumor Effects of IL-27	70
3.5.6	Therapeutic Potential of IL-27 in Oncology	72
	References	73